Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
June 20, 2024 at 11:22 AM EDT
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trialJune 20, 2024 at 11:22 AM EDT
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|